<article article-type="other"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15942629</article-id><article-id pub-id-type="pmc">2361806</article-id><article-id pub-id-type="pii">6602649</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6602649</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) <italic>vs</italic> 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moehler</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eimermacher</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Siebler</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Höhler</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wein</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Menges</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Flieger</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Junginger</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Geer</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Gracien</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Galle</surname><given-names>P R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Heike</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Klinikum der Johannes-Gutenberg-Universität, Mainz, Dortmund, Germany</aff><aff id="aff2"><label>2</label>Universtitätsklinik Erlangen, Erlangen, Dortmund, Germany</aff><aff id="aff3"><label>3</label>Universitätskliniken des Saarlandes, Homburg/Saar, Dortmund, Germany</aff><aff id="aff4"><label>4</label>Klinikum Aschaffenburg, Aschaffenburg, Dortmund, Germany</aff><aff id="aff5"><label>5</label>Diakonie Krankenhaus, Schwäbish Hall, Dortmund, Germany</aff><aff id="aff6"><label>6</label>Aventis Pharma Deutschland GmbH, Bad Soden/Ts</aff><aff id="aff7"><label>7</label>Med. Department Mitte, Klinikum Dortmund gGmbH, Beurhausstr. 10, Dortmund 44137, Germany</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xlink:href="mailto:michael.heike@klinikumdo.de">michael.heike@klinikumdo.de</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>06</month><year>2005</year></pub-date><pub-date pub-type="collection"><day>14</day><month>06</month><year>2005</year></pub-date><pub-date pub-type="ppub"><day>20</day><month>06</month><year>2005</year></pub-date><volume>92</volume><issue>12</issue><fpage>2122</fpage><lpage>2128</lpage><history><date date-type="received"><day>20</day><month>01</month><year>2005</year></date><date date-type="rev-recd"><day>13</day><month>04</month><year>2005</year></date><date date-type="accepted"><day>02</day><month>05</month><year>2005</year></date></history><copyright-statement>Copyright 2005, Cancer Research UK</copyright-statement><copyright-year>2005</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p><offsets xml_i="4494" xml_f="4818" txt_i="11" txt_f="335">An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m</offsets><sup><offsets xml_i="4823" xml_f="4825" txt_i="335" txt_f="337">−2</offsets></sup><offsets xml_i="4831" xml_f="4844" txt_i="337" txt_f="350">, LV 500 mg m</offsets><sup><offsets xml_i="4849" xml_f="4851" txt_i="350" txt_f="352">−2</offsets></sup><offsets xml_i="4857" xml_f="4878" txt_i="352" txt_f="373">, 24-h 5-FU 2000 mg m</offsets><sup><offsets xml_i="4883" xml_f="4885" txt_i="373" txt_f="375">−2</offsets></sup><offsets xml_i="4891" xml_f="4955" txt_i="375" txt_f="439">, and ELF comprised three once-daily doses of etoposide 120 mg m</offsets><sup><offsets xml_i="4960" xml_f="4962" txt_i="439" txt_f="441">−2</offsets></sup><offsets xml_i="4968" xml_f="4981" txt_i="441" txt_f="454">, LV 300 mg m</offsets><sup><offsets xml_i="4986" xml_f="4988" txt_i="454" txt_f="456">−2</offsets></sup><offsets xml_i="4994" xml_f="5009" txt_i="456" txt_f="471">, 5-FU 500 mg m</offsets><sup><offsets xml_i="5014" xml_f="5016" txt_i="471" txt_f="473">−2</offsets></sup><offsets xml_i="5022" xml_f="5349" txt_i="473" txt_f="800">. In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end point) were 30% for ILF and 17% for ELF (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.29–1.13, </offsets><italic><offsets xml_i="5357" xml_f="5358" txt_i="800" txt_f="801">P</offsets></italic><offsets xml_i="5367" xml_f="5507" txt_i="801" txt_f="941">=0.0766). Overall response rates over the entire treatment period for ILF and ELF were 43 and 24%, respectively (RR 0.56, 95% CI 0.33–0.97; </offsets><italic><offsets xml_i="5515" xml_f="5516" txt_i="941" txt_f="942">P</offsets></italic><offsets xml_i="5525" xml_f="5607" txt_i="942" txt_f="1024">=0.0467). For ILF and ELF, respectively, median progression-free survival was 4.5 </offsets><italic><offsets xml_i="5615" xml_f="5617" txt_i="1024" txt_f="1026">vs</offsets></italic><offsets xml_i="5626" xml_f="5673" txt_i="1026" txt_f="1073"> 2.3 months, time to treatment failure was 3.6 </offsets><italic><offsets xml_i="5681" xml_f="5683" txt_i="1073" txt_f="1075">vs</offsets></italic><offsets xml_i="5692" xml_f="5705" txt_i="1075" txt_f="1088"> 2.2 months (</offsets><italic><offsets xml_i="5713" xml_f="5714" txt_i="1088" txt_f="1089">P</offsets></italic><offsets xml_i="5723" xml_f="5763" txt_i="1089" txt_f="1129">=0.4542), and overall survival was 10.8 </offsets><italic><offsets xml_i="5771" xml_f="5773" txt_i="1129" txt_f="1131">vs</offsets></italic><offsets xml_i="5782" xml_f="5795" txt_i="1131" txt_f="1144"> 8.3 months (</offsets><italic><offsets xml_i="5803" xml_f="5804" txt_i="1144" txt_f="1145">P</offsets></italic><offsets xml_i="5813" xml_f="6139" txt_i="1145" txt_f="1471">=0.2818). Both regimens were well tolerated, the main grade 3/4 toxicities being diarrhoea (18%, ILF) and neutropenia (57%, ELF). The data from this randomised phase II study indicate that ILF provides a better response rate than ELF, and that ILF should be investigated further for the treatment of metastatic gastric cancer.</offsets></p></abstract><kwd-group><kwd>ELF</kwd><kwd>5-fluorouracil</kwd><kwd>gastric</kwd><kwd>ILF</kwd><kwd>irinotecan</kwd><kwd>metastatic</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="6322" xml_f="6429" txt_i="1479" txt_f="1586">Gastric cancer is the fourth most common cancer in Europe and the third leading cause of cancer mortality (</offsets><xref ref-type="other" rid="bib6"><offsets xml_i="6463" xml_f="6468" txt_i="1586" txt_f="1591">Bray </offsets><italic><offsets xml_i="6476" xml_f="6481" txt_i="1591" txt_f="1596">et al</offsets></italic><offsets xml_i="6490" xml_f="6496" txt_i="1596" txt_f="1602">, 2002</offsets></xref><offsets xml_i="6503" xml_f="6642" txt_i="1602" txt_f="1741">). Although gastric cancer has declined over the past 50 years, the incidence of tumours at the gastro-oesophageal junction has increased (</offsets><xref ref-type="other" rid="bib3"><offsets xml_i="6676" xml_f="6681" txt_i="1741" txt_f="1746">Blot </offsets><italic><offsets xml_i="6689" xml_f="6694" txt_i="1746" txt_f="1751">et al</offsets></italic><offsets xml_i="6703" xml_f="6709" txt_i="1751" txt_f="1757">, 1991</offsets></xref><offsets xml_i="6716" xml_f="6840" txt_i="1757" txt_f="1881">). The use of chemotherapy for the management of patients with advanced gastric cancer, who have limited treatment options (</offsets><xref ref-type="other" rid="bib11"><offsets xml_i="6875" xml_f="6906" txt_i="1881" txt_f="1912">Hohenberger and Gretschel, 2003</offsets></xref><offsets xml_i="6913" xml_f="6974" txt_i="1912" txt_f="1973">), has only become widely acceptable over the last 20 years (</offsets><xref ref-type="other" rid="bib10"><offsets xml_i="7009" xml_f="7019" txt_i="1973" txt_f="1983">Glimelius </offsets><italic><offsets xml_i="7027" xml_f="7032" txt_i="1983" txt_f="1988">et al</offsets></italic><offsets xml_i="7041" xml_f="7047" txt_i="1988" txt_f="1994">, 1997</offsets></xref><offsets xml_i="7054" xml_f="7056" txt_i="1994" txt_f="1996">; </offsets><xref ref-type="other" rid="bib16"><offsets xml_i="7091" xml_f="7097" txt_i="1996" txt_f="2002">Murad </offsets><italic><offsets xml_i="7105" xml_f="7110" txt_i="2002" txt_f="2007">et al</offsets></italic><offsets xml_i="7119" xml_f="7125" txt_i="2007" txt_f="2013">, 1993</offsets></xref><offsets xml_i="7132" xml_f="7134" txt_i="2013" txt_f="2015">; </offsets><xref ref-type="other" rid="bib19"><offsets xml_i="7169" xml_f="7178" txt_i="2015" txt_f="2024">Pyrhonen </offsets><italic><offsets xml_i="7186" xml_f="7191" txt_i="2024" txt_f="2029">et al</offsets></italic><offsets xml_i="7200" xml_f="7206" txt_i="2029" txt_f="2035">, 1995</offsets></xref><offsets xml_i="7213" xml_f="7215" txt_i="2035" txt_f="2037">).</offsets></p><p><offsets xml_i="7222" xml_f="7552" txt_i="2038" txt_f="2368">5-Fluorouracil (5-FU), usually in combination with leucovorin (LV, also referred to as folinic acid), forms the basis of most chemotherapy regimens used for the treatment of gastric cancer. A randomised phase III trial compared combinations of 5-FU with other active drugs in advanced gastric cancer: etoposide, LV and 5-FU (ELF) </offsets><italic><offsets xml_i="7560" xml_f="7562" txt_i="2368" txt_f="2370">vs</offsets></italic><offsets xml_i="7571" xml_f="7609" txt_i="2370" txt_f="2408"> infusional 5-FU plus cisplatin (FUP) </offsets><italic><offsets xml_i="7617" xml_f="7619" txt_i="2408" txt_f="2410">vs</offsets></italic><offsets xml_i="7628" xml_f="7673" txt_i="2410" txt_f="2455"> 5-FU, doxorubicin and methotrexate (FAMTX) (</offsets><xref ref-type="other" rid="bib26"><offsets xml_i="7708" xml_f="7718" txt_i="2455" txt_f="2465">Vanhoefer </offsets><italic><offsets xml_i="7726" xml_f="7731" txt_i="2465" txt_f="2470">et al</offsets></italic><offsets xml_i="7740" xml_f="7746" txt_i="2470" txt_f="2476">, 2000</offsets></xref><offsets xml_i="7753" xml_f="8320" txt_i="2476" txt_f="3043">). The overall response rates (ORRs) ranged from 9% (ELF) to 20% (FUP) and median survival times were between 6.7 months (FAMTX) and 7.2 months (both ELF and FUP). The observed differences were not statistically significant and there is still no definitive regimen for the treatment of gastric cancer. The combination of epirubicin, cisplatin and continuous infusion 5-FU (ECF) has been proposed as a standard first-line therapy for gastric cancer as a consequence of its significantly improved response rate (46%) and survival (8.7 months) when compared with FAMTX (</offsets><xref ref-type="other" rid="bib27"><offsets xml_i="8355" xml_f="8362" txt_i="3043" txt_f="3050">Waters </offsets><italic><offsets xml_i="8370" xml_f="8375" txt_i="3050" txt_f="3055">et al</offsets></italic><offsets xml_i="8384" xml_f="8390" txt_i="3055" txt_f="3061">, 1999</offsets></xref><offsets xml_i="8397" xml_f="8593" txt_i="3061" txt_f="3257">). More recently, ELF has been shown to provide better disease control (complete response (CR)+partial response (PR)+stable disease (SD)) for patients with proximal rather than distal tumours (85 </offsets><italic><offsets xml_i="8601" xml_f="8603" txt_i="3257" txt_f="3259">vs</offsets></italic><offsets xml_i="8612" xml_f="8618" txt_i="3259" txt_f="3265"> 48%, </offsets><italic><offsets xml_i="8626" xml_f="8627" txt_i="3265" txt_f="3266">P</offsets></italic><offsets xml_i="8636" xml_f="8644" txt_i="3266" txt_f="3274">=0.04) (</offsets><xref ref-type="other" rid="bib24"><offsets xml_i="8679" xml_f="8697" txt_i="3274" txt_f="3292">Schulze-Bergkamen </offsets><italic><offsets xml_i="8705" xml_f="8710" txt_i="3292" txt_f="3297">et al</offsets></italic><offsets xml_i="8719" xml_f="8725" txt_i="3297" txt_f="3303">, 2002</offsets></xref><offsets xml_i="8732" xml_f="8962" txt_i="3303" txt_f="3533">). Tolerability, toxicity and ease of administration have become major determinants for selecting an appropriate therapy and ELF has emerged as a convenient, well-tolerated regimen that can be administered on an outpatient basis (</offsets><xref ref-type="other" rid="bib26"><offsets xml_i="8997" xml_f="9007" txt_i="3533" txt_f="3543">Vanhoefer </offsets><italic><offsets xml_i="9015" xml_f="9020" txt_i="3543" txt_f="3548">et al</offsets></italic><offsets xml_i="9029" xml_f="9035" txt_i="3548" txt_f="3554">, 2000</offsets></xref><offsets xml_i="9042" xml_f="9044" txt_i="3554" txt_f="3556">; </offsets><xref ref-type="other" rid="bib24"><offsets xml_i="9079" xml_f="9097" txt_i="3556" txt_f="3574">Schulze-Bergkamen </offsets><italic><offsets xml_i="9105" xml_f="9110" txt_i="3574" txt_f="3579">et al</offsets></italic><offsets xml_i="9119" xml_f="9125" txt_i="3579" txt_f="3585">, 2002</offsets></xref><offsets xml_i="9132" xml_f="9134" txt_i="3585" txt_f="3587">).</offsets></p><p><offsets xml_i="9141" xml_f="9412" txt_i="3588" txt_f="3859">Irinotecan (CPT-11, Camptosar; Pfizer Oncology, New York, USA) inhibits topoisomerase I thereby disrupting DNA replication and cell division within tumour cells. Response rates between 20 and 23% have been reported for irinotecan monotherapy in untreated gastric cancer (</offsets><xref ref-type="other" rid="bib9"><offsets xml_i="9446" xml_f="9456" txt_i="3859" txt_f="3869">Futatsuki </offsets><italic><offsets xml_i="9464" xml_f="9469" txt_i="3869" txt_f="3874">et al</offsets></italic><offsets xml_i="9478" xml_f="9484" txt_i="3874" txt_f="3880">, 1994</offsets></xref><offsets xml_i="9491" xml_f="9493" txt_i="3880" txt_f="3882">; </offsets><xref ref-type="other" rid="bib12"><offsets xml_i="9528" xml_f="9534" txt_i="3882" txt_f="3888">Kohne </offsets><italic><offsets xml_i="9542" xml_f="9547" txt_i="3888" txt_f="3893">et al</offsets></italic><offsets xml_i="9556" xml_f="9562" txt_i="3893" txt_f="3899">, 2003</offsets></xref><offsets xml_i="9569" xml_f="9637" txt_i="3899" txt_f="3967">). In patients who had failed previous therapy, irinotecan (180 mg m</offsets><sup><offsets xml_i="9642" xml_f="9644" txt_i="3967" txt_f="3969">−2</offsets></sup><offsets xml_i="9650" xml_f="9680" txt_i="3969" txt_f="3999">) combined with 5-FU (400 mg m</offsets><sup><offsets xml_i="9685" xml_f="9687" txt_i="3999" txt_f="4001">−2</offsets></sup><offsets xml_i="9693" xml_f="9718" txt_i="4001" txt_f="4026">, bolus) and LV (125 mg m</offsets><sup><offsets xml_i="9723" xml_f="9725" txt_i="4026" txt_f="4028">−2</offsets></sup><offsets xml_i="9731" xml_f="9769" txt_i="4028" txt_f="4066">) followed by 5-FU infusion (1200 mg m</offsets><sup><offsets xml_i="9774" xml_f="9776" txt_i="4066" txt_f="4068">−2</offsets></sup><offsets xml_i="9782" xml_f="9871" txt_i="4068" txt_f="4157"> over 48 h) yielded a response rate of 29%, while a further 34% of patients achieved SD (</offsets><xref ref-type="other" rid="bib1"><offsets xml_i="9905" xml_f="9915" txt_i="4157" txt_f="4167">Assersohn </offsets><italic><offsets xml_i="9923" xml_f="9928" txt_i="4167" txt_f="4172">et al</offsets></italic><offsets xml_i="9937" xml_f="9943" txt_i="4172" txt_f="4178">, 2004</offsets></xref><offsets xml_i="9950" xml_f="10062" txt_i="4178" txt_f="4290">). Irinotecan with bolus-LV/5-FU in the first-line treatment of gastric cancer provided a response rate of 22% (</offsets><xref ref-type="other" rid="bib2"><offsets xml_i="10096" xml_f="10103" txt_i="4290" txt_f="4297">Blanke </offsets><italic><offsets xml_i="10111" xml_f="10116" txt_i="4297" txt_f="4302">et al</offsets></italic><offsets xml_i="10125" xml_f="10131" txt_i="4302" txt_f="4308">, 2001</offsets></xref><offsets xml_i="10138" xml_f="10183" txt_i="4308" txt_f="4353">). However, this regimen (irinotecan 125 mg m</offsets><sup><offsets xml_i="10188" xml_f="10190" txt_i="4353" txt_f="4355">−2</offsets></sup><offsets xml_i="10196" xml_f="10208" txt_i="4355" txt_f="4367">, LV 20 mg m</offsets><sup><offsets xml_i="10213" xml_f="10215" txt_i="4367" txt_f="4369">−2</offsets></sup><offsets xml_i="10221" xml_f="10240" txt_i="4369" txt_f="4388"> plus 5-FU 500 mg m</offsets><sup><offsets xml_i="10245" xml_f="10247" txt_i="4388" txt_f="4390">−2</offsets></sup><offsets xml_i="10253" xml_f="10449" txt_i="4390" txt_f="4586">, all given weekly for 4 weeks followed by a 2-week rest) was associated with a high incidence of severe diarrhoea (28%) and neutropenia (36%) infection leading to substantial dose modifications (</offsets><xref ref-type="other" rid="bib2"><offsets xml_i="10483" xml_f="10490" txt_i="4586" txt_f="4593">Blanke </offsets><italic><offsets xml_i="10498" xml_f="10503" txt_i="4593" txt_f="4598">et al</offsets></italic><offsets xml_i="10512" xml_f="10518" txt_i="4598" txt_f="4604">, 2001</offsets></xref><offsets xml_i="10525" xml_f="10715" txt_i="4604" txt_f="4794">). By comparison, the combination of irinotecan with continuous rather than bolus infusions of LV/5-FU exhibited a lower incidence of grade 3 and 4 toxicities in colorectal cancer patients (</offsets><xref ref-type="other" rid="bib8"><offsets xml_i="10749" xml_f="10759" txt_i="4794" txt_f="4804">Douillard </offsets><italic><offsets xml_i="10767" xml_f="10772" txt_i="4804" txt_f="4809">et al</offsets></italic><offsets xml_i="10781" xml_f="10787" txt_i="4809" txt_f="4815">, 2000</offsets></xref><offsets xml_i="10794" xml_f="10796" txt_i="4815" txt_f="4817">; </offsets><xref ref-type="other" rid="bib22"><offsets xml_i="10831" xml_f="10837" txt_i="4817" txt_f="4823">Saltz </offsets><italic><offsets xml_i="10845" xml_f="10850" txt_i="4823" txt_f="4828">et al</offsets></italic><offsets xml_i="10859" xml_f="10865" txt_i="4828" txt_f="4834">, 2000</offsets></xref><offsets xml_i="10872" xml_f="10874" txt_i="4834" txt_f="4836">; </offsets><xref ref-type="other" rid="bib5"><offsets xml_i="10908" xml_f="10915" txt_i="4836" txt_f="4843">Bouzid </offsets><italic><offsets xml_i="10923" xml_f="10928" txt_i="4843" txt_f="4848">et al</offsets></italic><offsets xml_i="10937" xml_f="10943" txt_i="4848" txt_f="4854">, 2003</offsets></xref><offsets xml_i="10950" xml_f="11021" txt_i="4854" txt_f="4925">). Therefore, we have investigated a weekly dose of irinotecan (80 mg m</offsets><sup><offsets xml_i="11026" xml_f="11028" txt_i="4925" txt_f="4927">−2</offsets></sup><offsets xml_i="11034" xml_f="11068" txt_i="4927" txt_f="4961">) in combination with LV (500 mg m</offsets><sup><offsets xml_i="11073" xml_f="11075" txt_i="4961" txt_f="4963">−2</offsets></sup><offsets xml_i="11081" xml_f="11113" txt_i="4963" txt_f="4995">) and continuous 5-FU (2000 mg m</offsets><sup><offsets xml_i="11118" xml_f="11120" txt_i="4995" txt_f="4997">−2</offsets></sup><offsets xml_i="11126" xml_f="11427" txt_i="4997" txt_f="5298"> over 24 h) according to the AIO (Arbeitsgemeinschaft Internistische Onkologie) regimen (i.e. ILF) in gastric cancer patients. In a previous phase I study of ILF in the first- and second-line treatment of gastric cancer, we observed a response rate of 20% with a further 36% of patients reporting SD (</offsets><xref ref-type="other" rid="bib15"><offsets xml_i="11462" xml_f="11470" txt_i="5298" txt_f="5306">Moehler </offsets><italic><offsets xml_i="11478" xml_f="11483" txt_i="5306" txt_f="5311">et al</offsets></italic><offsets xml_i="11492" xml_f="11498" txt_i="5311" txt_f="5317">, 2003</offsets></xref><offsets xml_i="11505" xml_f="11778" txt_i="5317" txt_f="5590">). Importantly, toxicity was sufficiently manageable to allow outpatient-based treatment. Therefore, we initiated the present randomised, controlled, phase II study to compare the efficacy and safety of ILF with ELF in the first-line treatment of metastatic gastric cancer.</offsets></p><sec sec-type="methods"><title><offsets xml_i="11813" xml_f="11833" txt_i="5591" txt_f="5611">PATIENTS AND METHODS</offsets></title><sec><title><offsets xml_i="11853" xml_f="11861" txt_i="5612" txt_f="5620">Patients</offsets></title><p><offsets xml_i="11872" xml_f="12272" txt_i="5621" txt_f="6018">Eligible patients had untreated histologically proven gastric adenocarcinoma, or adenocarcinoma of the oesophagogastric junction with measurable metastatic disease and/or locally recurrent nodal involvement, were aged between 18 and 75 years with a Karnofsky performance score (KPS) ⩾60 and a life expectancy &gt;12 weeks. Patients were required to have adequate haematological (neutrophils ⩾2.0 × 10</offsets><sup><offsets xml_i="12277" xml_f="12278" txt_i="6018" txt_f="6019">9</offsets></sup><offsets xml_i="12284" xml_f="12286" txt_i="6019" txt_f="6021"> l</offsets><sup><offsets xml_i="12291" xml_f="12293" txt_i="6021" txt_f="6023">−1</offsets></sup><offsets xml_i="12299" xml_f="12320" txt_i="6023" txt_f="6044">, platelets ⩾150 × 10</offsets><sup><offsets xml_i="12325" xml_f="12326" txt_i="6044" txt_f="6045">9</offsets></sup><offsets xml_i="12332" xml_f="12334" txt_i="6045" txt_f="6047"> l</offsets><sup><offsets xml_i="12339" xml_f="12341" txt_i="6047" txt_f="6049">−1</offsets></sup><offsets xml_i="12347" xml_f="12368" txt_i="6049" txt_f="6070">; haemoglobin ⩾10g dl</offsets><sup><offsets xml_i="12373" xml_f="12375" txt_i="6070" txt_f="6072">−1</offsets></sup><offsets xml_i="12381" xml_f="12622" txt_i="6072" txt_f="6310">), hepatic (total bilirubin ⩽1.25 × upper normal limit (UNL); aspartate (AST) and alanine (ALT) aminotransferases ⩽3 × UNL) and renal function (creatinine &lt;1.25 × UNL). Patients with previous cancer therapies were excluded from the study.</offsets></p><p><offsets xml_i="12629" xml_f="12999" txt_i="6311" txt_f="6681">All patients provided signed and dated consent before entering the trial. The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines and the protocol was initially approved by the Ethics committee of Aerztekammer Rheinland-Pfalz and later by all Ethics committees responsible for participating centres.</offsets></p></sec><sec><title><offsets xml_i="13021" xml_f="13051" txt_i="6683" txt_f="6713">Study design and randomisation</offsets></title><p><offsets xml_i="13062" xml_f="13407" txt_i="6714" txt_f="7059">This was an open-label, multicentre, phase II randomised trial with two treatment arms. Patients were randomly assigned and stratified according to centre, peritoneal involvement (yes/no) and prior gastrectomy (yes/no). The randomisation process was centralised and performed by the Coordination Centre for Clinical Trials (KKS), Mainz, Germany.</offsets></p></sec><sec><title><offsets xml_i="13429" xml_f="13478" txt_i="7061" txt_f="7110">Administration of study drugs and dose adjustment</offsets></title><p><offsets xml_i="13489" xml_f="13549" txt_i="7111" txt_f="7171">Patients assigned to ILF (Arm A) received irinotecan 80 mg m</offsets><sup><offsets xml_i="13554" xml_f="13556" txt_i="7171" txt_f="7173">−2</offsets></sup><offsets xml_i="13562" xml_f="13622" txt_i="7173" txt_f="7233"> intravenously (i.v.) over 60–90 min followed by LV 500 mg m</offsets><sup><offsets xml_i="13627" xml_f="13629" txt_i="7233" txt_f="7235">−2</offsets></sup><offsets xml_i="13635" xml_f="13676" txt_i="7235" txt_f="7276"> i.v. over 60 min and then 5-FU 2000 mg m</offsets><sup><offsets xml_i="13681" xml_f="13683" txt_i="7276" txt_f="7278">−2</offsets></sup><offsets xml_i="13689" xml_f="14460" txt_i="7278" txt_f="8046"> i.v. over 24 h, on day 1. Each cycle comprised six once-weekly treatments followed by a 13-day rest period. Systemic prophylactic atropine (0.25 mg) injections for irinotecan-related acute cholinergic symptoms were allowed for the first cycle but not recommended. Prophylactic treatment for delayed diarrhoea was not permitted. However, patients were carefully informed of the potential risk of delayed diarrhoea and neutropenia and the need for early intervention with loperamide, metoclopramide, antibiotics, or hospitalisation and parenteral rehydration in case of refractory diarrhoea (&gt;48 h). Antiemetic treatment was performed using metoclopramide or HT-3 antagonists in a sequential manner. The prophylactic use of colony-stimulating factors was not permitted.</offsets></p><p><offsets xml_i="14467" xml_f="14527" txt_i="8047" txt_f="8107">Patients assigned to ELF (Arm B) received etoposide 120 mg m</offsets><sup><offsets xml_i="14532" xml_f="14534" txt_i="8107" txt_f="8109">−2</offsets></sup><offsets xml_i="14540" xml_f="14570" txt_i="8109" txt_f="8139"> i.v. over 60 min, LV 300 mg m</offsets><sup><offsets xml_i="14575" xml_f="14577" txt_i="8139" txt_f="8141">−2</offsets></sup><offsets xml_i="14583" xml_f="14625" txt_i="8141" txt_f="8183"> i.v. over 5–10 min and then 5-FU 500 mg m</offsets><sup><offsets xml_i="14630" xml_f="14632" txt_i="8183" txt_f="8185">−2</offsets></sup><offsets xml_i="14638" xml_f="14767" txt_i="8185" txt_f="8314"> bolus i.v. over 2–4 min, on day 1. Each cycle comprised three applications on consecutive days (1–3) followed by an 18-day rest.</offsets></p><p><offsets xml_i="14774" xml_f="15194" txt_i="8315" txt_f="8735">All study treatments were administered until disease progression, unacceptable toxicity or withdrawal of consent. In the event of toxicity (defined by the National Cancer Institute of Canada expanded common toxicity criteria; NCIC-CTC), treatment delays or dose reductions could be applied as follows. If at any time during a cycle there were moderate reductions in haematological function (neutrophil count 0.5–1.5 × 10</offsets><sup><offsets xml_i="15199" xml_f="15200" txt_i="8735" txt_f="8736">9</offsets></sup><offsets xml_i="15206" xml_f="15208" txt_i="8736" txt_f="8738"> l</offsets><sup><offsets xml_i="15213" xml_f="15215" txt_i="8738" txt_f="8740">−1</offsets></sup><offsets xml_i="15221" xml_f="15248" txt_i="8740" txt_f="8767">, platelet count 25–75 × 10</offsets><sup><offsets xml_i="15253" xml_f="15254" txt_i="8767" txt_f="8768">9</offsets></sup><offsets xml_i="15260" xml_f="15262" txt_i="8768" txt_f="8770"> l</offsets><sup><offsets xml_i="15267" xml_f="15269" txt_i="8770" txt_f="8772">−1</offsets></sup><offsets xml_i="15275" xml_f="15468" txt_i="8772" txt_f="8959">) or moderate diarrhoea or stomatitis (&gt;grade 1), the next administration could be delayed for up to 2 weeks. If at any time haematological abnormalities were noted (neutrophils &lt;0.5 × 10</offsets><sup><offsets xml_i="15473" xml_f="15474" txt_i="8959" txt_f="8960">9</offsets></sup><offsets xml_i="15480" xml_f="15482" txt_i="8960" txt_f="8962"> l</offsets><sup><offsets xml_i="15487" xml_f="15489" txt_i="8962" txt_f="8964">−1</offsets></sup><offsets xml_i="15495" xml_f="15519" txt_i="8964" txt_f="8985">, neutrophils &lt;1 × 10</offsets><sup><offsets xml_i="15524" xml_f="15525" txt_i="8985" txt_f="8986">9</offsets></sup><offsets xml_i="15531" xml_f="15533" txt_i="8986" txt_f="8988"> l</offsets><sup><offsets xml_i="15538" xml_f="15540" txt_i="8988" txt_f="8990">−1</offsets></sup><offsets xml_i="15546" xml_f="15593" txt_i="8990" txt_f="9034"> with infection or fever, platelets &lt;25 × 10</offsets><sup><offsets xml_i="15598" xml_f="15599" txt_i="9034" txt_f="9035">9</offsets></sup><offsets xml_i="15605" xml_f="15607" txt_i="9035" txt_f="9037"> l</offsets><sup><offsets xml_i="15612" xml_f="15614" txt_i="9037" txt_f="9039">−1</offsets></sup><offsets xml_i="15620" xml_f="15857" txt_i="9039" txt_f="9276">) or if there were ⩾grade 3 or 4 diarrhoea or stomatitis, treatment had to be delayed until recovery to moderate levels (as described above) after which the following dose reductions were applied. For Arm A, 5-FU was reduced to 1600 mg m</offsets><sup><offsets xml_i="15862" xml_f="15864" txt_i="9276" txt_f="9278">−2</offsets></sup><offsets xml_i="15870" xml_f="15896" txt_i="9278" txt_f="9304"> and irinotecan to 65 mg m</offsets><sup><offsets xml_i="15901" xml_f="15903" txt_i="9304" txt_f="9306">−2</offsets></sup><offsets xml_i="15909" xml_f="16001" txt_i="9306" txt_f="9398">. For Arm B, in the case of haematological toxicity, etoposide had to be reduced to 100 mg m</offsets><sup><offsets xml_i="16006" xml_f="16008" txt_i="9398" txt_f="9400">−2</offsets></sup><offsets xml_i="16014" xml_f="16035" txt_i="9400" txt_f="9421"> and 5-FU to 400 mg m</offsets><sup><offsets xml_i="16040" xml_f="16042" txt_i="9421" txt_f="9423">−2</offsets></sup><offsets xml_i="16048" xml_f="16122" txt_i="9423" txt_f="9497">, and in the case of diarrhoea or stomatitis, 5-FU was reduced to 400 mg m</offsets><sup><offsets xml_i="16127" xml_f="16129" txt_i="9497" txt_f="9499">−2</offsets></sup><offsets xml_i="16135" xml_f="16631" txt_i="9499" txt_f="9989">. If a condition persisted despite dose reduction, or if a patient experienced myocardial infarction, treatment was terminated. In the case of hand–foot syndrome, the dose of 5-FU was to be reduced by 20%. Delayed diarrhoea was treated immediately with loperamide and rehydration and, if associated with severe neutropenia, a broad-spectrum antibiotic. Hospitalisation with i.v. rehydration was required for grade 4 or persistent (&gt;48 h) diarrhoea, concomitant vomiting, fever, or KPS &lt;60%.</offsets></p></sec><sec><title><offsets xml_i="16653" xml_f="16670" txt_i="9991" txt_f="10008">Study evaluations</offsets></title><p><offsets xml_i="16681" xml_f="16931" txt_i="10009" txt_f="10259">At baseline up to five measurable lesions per organ and 10 lesions in total were to be identified as target lesions, measured using computed tomography (CT), and recorded according to the RECIST system (Response Evaluation Criteria In Solid Tumours; </offsets><xref ref-type="other" rid="bib25"><offsets xml_i="16966" xml_f="16975" txt_i="10259" txt_f="10268">Therasse </offsets><italic><offsets xml_i="16983" xml_f="16988" txt_i="10268" txt_f="10273">et al</offsets></italic><offsets xml_i="16997" xml_f="17003" txt_i="10273" txt_f="10279">, 2000</offsets></xref><offsets xml_i="17010" xml_f="18062" txt_i="10279" txt_f="11331">). The sum of the longest diameters for all target lesions was used as a reference for determining objective tumour response. Tumour responses were evaluated at week 7, week 14 and then every two cycles for patients receiving ILF or every four cycles for patients receiving ELF. Responses were determined according to RECIST as follows: complete response was defined as the disappearance of all target and nontarget lesions with no new lesions and confirmed by two observations at least 4 weeks apart; PR was defined as a reduction of 30% or more in the sums of the longest diameters of all measurable lesions relative to baseline with no new lesions; no change (NC) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) with no new lesions; and PD was defined as ⩾20% increase in the sum of the longest diameters, the occurrence of nontarget lesions (e.g. pleural effusion or ascites) or the appearance of brain metastases independently of performance at sites outside the brain.</offsets></p><p><offsets xml_i="18069" xml_f="18309" txt_i="11332" txt_f="11572">Safety and tolerability were assessed by regular clinical examinations and assessments of adverse events (weekly, at the end of treatment and at every 3 months of follow-up), disease symptoms, KPS, haematological and biochemical parameters.</offsets></p></sec><sec><title><offsets xml_i="18331" xml_f="18351" txt_i="11574" txt_f="11594">Statistical analysis</offsets></title><p><offsets xml_i="18362" xml_f="18585" txt_i="11595" txt_f="11818">The primary end point was objective clinical response (CR+PR) based on an interim analysis following 14 weeks of treatment. The one-sided exact Fisher's test was used to compare the treatment arms at the significance level </offsets><italic><offsets xml_i="18593" xml_f="18594" txt_i="11818" txt_f="11819">α</offsets></italic><offsets xml_i="18603" xml_f="18720" txt_i="11819" txt_f="11936">=5%. The analyses were performed on an intention-to-treat basis including all patients who were treated in the study.</offsets></p><p><offsets xml_i="18727" xml_f="18924" txt_i="11937" txt_f="12134">The secondary end points were ORR (for the entire treatment period), time to progression, tumour growth control, time to treatment failure (including progression, death or withdrawal) and survival.</offsets></p><p><offsets xml_i="18931" xml_f="19225" txt_i="12135" txt_f="12429">Time to event data were described by Kaplan–Meier estimates and treatment groups were compared by log-rank test. Time to event data were further evaluated by appropriate proportional Cox's models and results were summarised by hazard ratio point and 95% confidence interval (CI) estimates, and </offsets><italic><offsets xml_i="19233" xml_f="19234" txt_i="12429" txt_f="12430">P</offsets></italic><offsets xml_i="19243" xml_f="19259" txt_i="12430" txt_f="12446">-values of Wald </offsets><italic><offsets xml_i="19267" xml_f="19268" txt_i="12446" txt_f="12447">χ</offsets></italic><sup><offsets xml_i="19282" xml_f="19283" txt_i="12447" txt_f="12448">2</offsets></sup><offsets xml_i="19289" xml_f="19570" txt_i="12448" txt_f="12729"> test. Binary data were described by risk ratio (RR) point and 95% CI estimates and treatment groups were compared by exact Fisher's test. Binary data were further evaluated by appropriate logistic regression models and were summarised by odds ratio point and 95% CI estimates and </offsets><italic><offsets xml_i="19578" xml_f="19579" txt_i="12729" txt_f="12730">P</offsets></italic><offsets xml_i="19588" xml_f="19604" txt_i="12730" txt_f="12746">-values of Wald </offsets><italic><offsets xml_i="19612" xml_f="19613" txt_i="12746" txt_f="12747">χ</offsets></italic><sup><offsets xml_i="19627" xml_f="19628" txt_i="12747" txt_f="12748">2</offsets></sup><offsets xml_i="19634" xml_f="19669" txt_i="12748" txt_f="12783"> test. If not specified otherwise, </offsets><italic><offsets xml_i="19677" xml_f="19678" txt_i="12783" txt_f="12784">P</offsets></italic><offsets xml_i="19687" xml_f="19817" txt_i="12784" txt_f="12914">-values are presented from two-sided tests and two-sided 95% CI are presented. All analyses were performed using SAS version 6.12.</offsets></p></sec></sec><sec><title><offsets xml_i="19845" xml_f="19852" txt_i="12917" txt_f="12924">RESULTS</offsets></title><sec><title><offsets xml_i="19872" xml_f="19895" txt_i="12925" txt_f="12948">Patient characteristics</offsets></title><p><offsets xml_i="19906" xml_f="20300" txt_i="12949" txt_f="13343">In all, 120 patients from 17 centres in Germany were randomised into the study between November 2000 and April 2003. Two patients from Arm A and four from Arm B withdrew without receiving study treatment; therefore, the intention-to-treat population contained 114 patients (56 received ILF and 58 received ELF). The baseline characteristics were well balanced between the two treatment groups (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="20334" xml_f="20341" txt_i="13343" txt_f="13350">Table 1</offsets></xref><offsets xml_i="20348" xml_f="20598" txt_i="13350" txt_f="13600">). The median age of patients was 62 years and the median KPS was 90%. In around one-third (31%) of patients, the primary tumour site was the oesophagogastric junction, 62% of patients had liver metastases and in 77% two or more organs were involved.</offsets></p></sec><sec><title><offsets xml_i="20620" xml_f="20634" txt_i="13602" txt_f="13616">Response rates</offsets></title><p><offsets xml_i="20645" xml_f="20806" txt_i="13617" txt_f="13778">The objective clinical response rates following 14 weeks of treatment (primary end point) were 30% for ILF compared with 17% for ELF (RR 0.57, 95% CI 0.29–1.13, </offsets><italic><offsets xml_i="20814" xml_f="20815" txt_i="13778" txt_f="13779">P</offsets></italic><offsets xml_i="20824" xml_f="20994" txt_i="13779" txt_f="13949">=0.0766). The ORRs for the entire treatment period and including all assessments prior to discontinuation were 43% (24 of the 56) for ILF and 24% (14 of the 58) for ELF (</offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="21028" xml_f="21035" txt_i="13949" txt_f="13956">Table 2</offsets></xref><offsets xml_i="21042" xml_f="21165" txt_i="13956" txt_f="14079">). The increased response rate provided by ILF compared with ELF was statistically significant (RR=0.56; 95% CI=0.33–0.97; </offsets><italic><offsets xml_i="21173" xml_f="21174" txt_i="14079" txt_f="14080">P</offsets></italic><offsets xml_i="21183" xml_f="21290" txt_i="14080" txt_f="14187">=0.0467.) The tumour control rates (CR+PR+NC) were 63% (35 of the 56) and 41% (24 of the 58), respectively.</offsets></p><p><offsets xml_i="21297" xml_f="21460" txt_i="14188" txt_f="14351">Logistic regression analysis indicated that a baseline KPS ⩽80% reduced the likelihood of a response by 59% compared with patients whose KPS was greater than 80% (</offsets><italic><offsets xml_i="21468" xml_f="21469" txt_i="14351" txt_f="14352">P</offsets></italic><offsets xml_i="21478" xml_f="21487" txt_i="14352" txt_f="14361">=0.038) (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="21521" xml_f="21528" txt_i="14361" txt_f="14368">Table 3</offsets></xref><offsets xml_i="21535" xml_f="21746" txt_i="14368" txt_f="14579">). After adjustment for KPS, peritoneal involvement and surgery for primary tumour, the regression model also demonstrated that ILF was 138% more likely to provide a response when compared with the ELF regimen (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="21780" xml_f="21787" txt_i="14579" txt_f="14586">Table 3</offsets></xref><offsets xml_i="21794" xml_f="21796" txt_i="14586" txt_f="14588">, </offsets><italic><offsets xml_i="21804" xml_f="21805" txt_i="14588" txt_f="14589">P</offsets></italic><offsets xml_i="21814" xml_f="21822" txt_i="14589" txt_f="14597">=0.042).</offsets></p></sec><sec><title><offsets xml_i="21844" xml_f="21909" txt_i="14599" txt_f="14664">Progression-free survival, treatment failure and overall survival</offsets></title><p><offsets xml_i="21920" xml_f="22400" txt_i="14665" txt_f="15145">At the last data cutoff, the median follow-up was 9.4 months in Arm A and 5.8 months in Arm B. At this time, 96 of the 114 patients had died. Disease progression was the major cause of death and accounted for 79% of patients in both treatment groups. One patient from the ILF arm did not comply with the provided recommendations for the treatment of prolonged grade 3 diarrhoea and consequently died (i.e. toxic death). One patient in the ELF arm died from a cardiovascular event.</offsets></p><p><offsets xml_i="22407" xml_f="22547" txt_i="15146" txt_f="15286">Compared with ELF, the ILF regimen extended median progression-free survival, median time to treatment failure and median overall survival (</offsets><xref rid="tbl4" ref-type="table"><offsets xml_i="22581" xml_f="22588" txt_i="15286" txt_f="15293">Table 4</offsets></xref><offsets xml_i="22595" xml_f="22805" txt_i="15293" txt_f="15503">). However, when the treatment groups were compared by log-rank test, there was no significant difference between the two treatments for any of these parameters (e.g. the Kaplan–Meier survival plot as shown in </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="22837" xml_f="22845" txt_i="15503" txt_f="15511">Figure 1</offsets></xref><offsets xml_i="22852" xml_f="22854" txt_i="15511" txt_f="15513">).</offsets></p><p><offsets xml_i="22861" xml_f="23066" txt_i="15514" txt_f="15719">Investigational analyses found that the risk of progression was increased in patients with a primary tumour in the oesophagogastric junction and in those with metastatic involvement in two or more organs (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="23100" xml_f="23107" txt_i="15719" txt_f="15726">Table 3</offsets></xref><offsets xml_i="23114" xml_f="23300" txt_i="15726" txt_f="15912">). As would be expected, the risk of death was increased in patients with a low KPS, in those with two or more involved organs and in those with peritoneal involvement who received ELF (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="23334" xml_f="23341" txt_i="15912" txt_f="15919">Table 3</offsets></xref><offsets xml_i="23348" xml_f="23350" txt_i="15919" txt_f="15921">).</offsets></p></sec><sec><title><offsets xml_i="23372" xml_f="23378" txt_i="15923" txt_f="15929">Safety</offsets></title><p><offsets xml_i="23389" xml_f="23494" txt_i="15930" txt_f="16035">The median number of cycles administered in the study was two for ILF (Arm A) and three for ELF (Arm B) (</offsets><xref rid="tbl5" ref-type="table"><offsets xml_i="23528" xml_f="23535" txt_i="16035" txt_f="16042">Table 5</offsets></xref><offsets xml_i="23542" xml_f="24104" txt_i="16042" txt_f="16604">). Although the median treatment duration period was over twice as long with ILF than with ELF, there were more dose administration delays (70%) and dose reductions (75%) with ILF than with ELF (52 and 45%, respectively). The main reason for discontinuing study treatment was disease progression; 54% of patients receiving ILF and 72% receiving ELF. Although only one patient in each treatment group withdrew because of treatment-related toxicity, five patients receiving ILF and three patients receiving ELF either withdrew consent or refused further treatment.</offsets></p><p><offsets xml_i="24111" xml_f="24285" txt_i="16605" txt_f="16779">The incidence of grade 3/4 haematological toxicities was low in both treatment groups with the exception of neutropenia, which was reported by 57% of patients receiving ELF (</offsets><xref rid="tbl6" ref-type="table"><offsets xml_i="24319" xml_f="24326" txt_i="16779" txt_f="16786">Table 6</offsets></xref><offsets xml_i="24333" xml_f="24634" txt_i="16786" txt_f="17087">). There were more grade 3/4 gastrointestinal toxic events with ILF, notably diarrhoea, which was reported by 18% of patients compared with no reports with ELF. Grade 3/4 alopecia was reported by a significant proportion of patients receiving ELF (28%), but was only seen in 5% of those receiving ILF.</offsets></p></sec></sec><sec><title><offsets xml_i="24662" xml_f="24672" txt_i="17090" txt_f="17100">DISCUSSION</offsets></title><p><offsets xml_i="24683" xml_f="24927" txt_i="17101" txt_f="17345">Although chemotherapy regimens offer at best a slight, albeit statistically significant, improvement in survival for patients with gastric cancer, they are associated with a degree of toxicity that limits their value as a palliative treatment (</offsets><xref ref-type="other" rid="bib26"><offsets xml_i="24962" xml_f="24972" txt_i="17345" txt_f="17355">Vanhoefer </offsets><italic><offsets xml_i="24980" xml_f="24985" txt_i="17355" txt_f="17360">et al</offsets></italic><offsets xml_i="24994" xml_f="25000" txt_i="17360" txt_f="17366">, 2000</offsets></xref><offsets xml_i="25007" xml_f="25009" txt_i="17366" txt_f="17368">; </offsets><xref ref-type="other" rid="bib23"><offsets xml_i="25044" xml_f="25059" txt_i="17368" txt_f="17383">Schoffski, 2002</offsets></xref><offsets xml_i="25066" xml_f="25068" txt_i="17383" txt_f="17385">; </offsets><xref ref-type="other" rid="bib7"><offsets xml_i="25102" xml_f="25118" txt_i="17385" txt_f="17401">Diaz-Rubio, 2004</offsets></xref><offsets xml_i="25125" xml_f="25127" txt_i="17401" txt_f="17403">).</offsets></p><p><offsets xml_i="25134" xml_f="25763" txt_i="17404" txt_f="18033">The primary end point of clinical response at 14 weeks was selected so that a statistical comparison at a fixed time point could be made. However, as it is the convention in such studies, patients were treated until progression, and could respond to treatment at a later point. Therefore, the overall response and survival rates obtained from the entire dosing period provide a more clinically significant assessment of the efficacy of these regimens for discussion in relation to other trials in gastric cancer. The irinotecan-based combination provided again a greater ORR than that seen with the commonly used ELF regimen (43 </offsets><italic><offsets xml_i="25771" xml_f="25773" txt_i="18033" txt_f="18035">vs</offsets></italic><offsets xml_i="25782" xml_f="25802" txt_i="18035" txt_f="18055"> 24%, respectively, </offsets><italic><offsets xml_i="25810" xml_f="25811" txt_i="18055" txt_f="18056">P</offsets></italic><offsets xml_i="25820" xml_f="25829" txt_i="18056" txt_f="18065">=0.0467).</offsets></p><p><offsets xml_i="25836" xml_f="25917" txt_i="18066" txt_f="18147">Overall response rates for ELF reported in previous studies range from 9 to 23% (</offsets><xref ref-type="other" rid="bib26"><offsets xml_i="25952" xml_f="25962" txt_i="18147" txt_f="18157">Vanhoefer </offsets><italic><offsets xml_i="25970" xml_f="25975" txt_i="18157" txt_f="18162">et al</offsets></italic><offsets xml_i="25984" xml_f="25990" txt_i="18162" txt_f="18168">, 2000</offsets></xref><offsets xml_i="25997" xml_f="25999" txt_i="18168" txt_f="18170">; </offsets><xref ref-type="other" rid="bib24"><offsets xml_i="26034" xml_f="26052" txt_i="18170" txt_f="18188">Schulze-Bergkamen </offsets><italic><offsets xml_i="26060" xml_f="26065" txt_i="18188" txt_f="18193">et al</offsets></italic><offsets xml_i="26074" xml_f="26080" txt_i="18193" txt_f="18199">, 2002</offsets></xref><offsets xml_i="26087" xml_f="26351" txt_i="18199" txt_f="18463">) and this compares well with the 24% response rate reported in this study. Accordingly, an ORR of nearly 50% for ILF, as seen in this study, is a substantial improvement and is in the range of previous reports of the use of this drug combination in this setting (</offsets><xref ref-type="other" rid="bib2"><offsets xml_i="26385" xml_f="26392" txt_i="18463" txt_f="18470">Blanke </offsets><italic><offsets xml_i="26400" xml_f="26405" txt_i="18470" txt_f="18475">et al</offsets></italic><offsets xml_i="26414" xml_f="26420" txt_i="18475" txt_f="18481">, 2001</offsets></xref><offsets xml_i="26427" xml_f="26429" txt_i="18481" txt_f="18483">; </offsets><xref ref-type="other" rid="bib15"><offsets xml_i="26464" xml_f="26472" txt_i="18483" txt_f="18491">Moehler </offsets><italic><offsets xml_i="26480" xml_f="26485" txt_i="18491" txt_f="18496">et al</offsets></italic><offsets xml_i="26494" xml_f="26500" txt_i="18496" txt_f="18502">, 2003</offsets></xref><offsets xml_i="26507" xml_f="26509" txt_i="18502" txt_f="18504">).</offsets></p><p><offsets xml_i="26516" xml_f="26693" txt_i="18505" txt_f="18682">The overall survival data in the present study also compare well with those from previous studies. The median overall survival with ELF has been reported at 7.2 and 8.0 months (</offsets><xref ref-type="other" rid="bib26"><offsets xml_i="26728" xml_f="26738" txt_i="18682" txt_f="18692">Vanhoefer </offsets><italic><offsets xml_i="26746" xml_f="26751" txt_i="18692" txt_f="18697">et al</offsets></italic><offsets xml_i="26760" xml_f="26766" txt_i="18697" txt_f="18703">, 2000</offsets></xref><offsets xml_i="26773" xml_f="26775" txt_i="18703" txt_f="18705">; </offsets><xref ref-type="other" rid="bib24"><offsets xml_i="26810" xml_f="26828" txt_i="18705" txt_f="18723">Schulze-Bergkamen </offsets><italic><offsets xml_i="26836" xml_f="26841" txt_i="18723" txt_f="18728">et al</offsets></italic><offsets xml_i="26850" xml_f="26856" txt_i="18728" txt_f="18734">, 2002</offsets></xref><offsets xml_i="26863" xml_f="27027" txt_i="18734" txt_f="18898">), which is similar to both the 8.3 months reported here and the data reported for irinotecan-based regimens in the second-line setting between 7.0 and 7.6 months (</offsets><xref ref-type="other" rid="bib15"><offsets xml_i="27062" xml_f="27070" txt_i="18898" txt_f="18906">Moehler </offsets><italic><offsets xml_i="27078" xml_f="27083" txt_i="18906" txt_f="18911">et al</offsets></italic><offsets xml_i="27092" xml_f="27098" txt_i="18911" txt_f="18917">, 2003</offsets></xref><offsets xml_i="27105" xml_f="27107" txt_i="18917" txt_f="18919">; </offsets><xref ref-type="other" rid="bib1"><offsets xml_i="27141" xml_f="27151" txt_i="18919" txt_f="18929">Assersohn </offsets><italic><offsets xml_i="27159" xml_f="27164" txt_i="18929" txt_f="18934">et al</offsets></italic><offsets xml_i="27173" xml_f="27179" txt_i="18934" txt_f="18940">, 2004</offsets></xref><offsets xml_i="27186" xml_f="27492" txt_i="18940" txt_f="19246">). By comparison, there was a nonsignificant trend for increased median survival with ILF in this study (10.8 months) and this compares well with data reported for more recent exploratory combinations such as capecitabine and docetaxel (10.5 months), and epirubicin, docetaxel and cisplatin (11.0 months) (</offsets><xref ref-type="other" rid="bib13"><offsets xml_i="27527" xml_f="27531" txt_i="19246" txt_f="19250">Lee </offsets><italic><offsets xml_i="27539" xml_f="27544" txt_i="19250" txt_f="19255">et al</offsets></italic><offsets xml_i="27553" xml_f="27559" txt_i="19255" txt_f="19261">, 2004</offsets></xref><offsets xml_i="27566" xml_f="27568" txt_i="19261" txt_f="19263">; </offsets><xref ref-type="other" rid="bib17"><offsets xml_i="27603" xml_f="27608" txt_i="19263" txt_f="19268">Park </offsets><italic><offsets xml_i="27616" xml_f="27621" txt_i="19268" txt_f="19273">et al</offsets></italic><offsets xml_i="27630" xml_f="27636" txt_i="19273" txt_f="19279">, 2004</offsets></xref><offsets xml_i="27643" xml_f="27835" txt_i="19279" txt_f="19471">). The same can be said of the progression-free survival period in the ILF group of 4.5 months, which compared well with the 4.1 and 5.2 months reported recently for docetaxel-based regimens (</offsets><xref ref-type="other" rid="bib13"><offsets xml_i="27870" xml_f="27874" txt_i="19471" txt_f="19475">Lee </offsets><italic><offsets xml_i="27882" xml_f="27887" txt_i="19475" txt_f="19480">et al</offsets></italic><offsets xml_i="27896" xml_f="27902" txt_i="19480" txt_f="19486">, 2004</offsets></xref><offsets xml_i="27909" xml_f="27911" txt_i="19486" txt_f="19488">; </offsets><xref ref-type="other" rid="bib17"><offsets xml_i="27946" xml_f="27951" txt_i="19488" txt_f="19493">Park </offsets><italic><offsets xml_i="27959" xml_f="27964" txt_i="19493" txt_f="19498">et al</offsets></italic><offsets xml_i="27973" xml_f="27979" txt_i="19498" txt_f="19504">, 2004</offsets></xref><offsets xml_i="27986" xml_f="28241" txt_i="19504" txt_f="19759">). In other randomised phase II studies, continuous 5-FU/LV infusion plus irinotecan has also provided promising efficacy (ORRs of 40–42%, median progression-free survival periods of 6.5–6.9 months and median overall survival periods of 10.7–11.3 months; </offsets><xref ref-type="other" rid="bib4"><offsets xml_i="28275" xml_f="28282" txt_i="19759" txt_f="19766">Bouche </offsets><italic><offsets xml_i="28290" xml_f="28295" txt_i="19766" txt_f="19771">et al</offsets></italic><offsets xml_i="28304" xml_f="28310" txt_i="19771" txt_f="19777">, 2004</offsets></xref><offsets xml_i="28317" xml_f="28319" txt_i="19777" txt_f="19779">; </offsets><xref ref-type="other" rid="bib18"><offsets xml_i="28354" xml_f="28360" txt_i="19779" txt_f="19785">Pozzo </offsets><italic><offsets xml_i="28368" xml_f="28373" txt_i="19785" txt_f="19790">et al</offsets></italic><offsets xml_i="28382" xml_f="28388" txt_i="19790" txt_f="19796">, 2004</offsets></xref><offsets xml_i="28395" xml_f="28540" txt_i="19796" txt_f="19941">). Consequently, large phase III studies are being considered to investigate irinotecan in combination with continuous 5-FU/LV infusion regimens.</offsets></p><p><offsets xml_i="28547" xml_f="29061" txt_i="19942" txt_f="20456">When patient histories, disease status and other factors were examined for their effects on clinical outcome, those patients who were in better general health (good performance status, low tumour burden) were more likely to achieve a response and less likely to have a progression event or die, regardless of the treatment arm to which they were randomised. Patients with peritoneal involvement at presentation have a generally poorer prognosis and as a group face a desperate need for improved treatment options (</offsets><xref ref-type="other" rid="bib20"><offsets xml_i="29096" xml_f="29100" txt_i="20456" txt_f="20460">Rau </offsets><italic><offsets xml_i="29108" xml_f="29113" txt_i="20460" txt_f="20465">et al</offsets></italic><offsets xml_i="29122" xml_f="29128" txt_i="20465" txt_f="20471">, 1996</offsets></xref><offsets xml_i="29135" xml_f="29375" txt_i="20471" txt_f="20711">). The data from this study demonstrated that these patients are less likely to suffer a fatal event if treated with ILF rather than ELF. This is potentially an important observation for the management of these difficult to treat patients (</offsets><xref ref-type="other" rid="bib3"><offsets xml_i="29409" xml_f="29414" txt_i="20711" txt_f="20716">Blot </offsets><italic><offsets xml_i="29422" xml_f="29427" txt_i="20716" txt_f="20721">et al</offsets></italic><offsets xml_i="29436" xml_f="29442" txt_i="20721" txt_f="20727">, 1991</offsets></xref><offsets xml_i="29449" xml_f="29451" txt_i="20727" txt_f="20729">; </offsets><xref ref-type="other" rid="bib6"><offsets xml_i="29485" xml_f="29490" txt_i="20729" txt_f="20734">Bray </offsets><italic><offsets xml_i="29498" xml_f="29503" txt_i="20734" txt_f="20739">et al</offsets></italic><offsets xml_i="29512" xml_f="29518" txt_i="20739" txt_f="20745">, 2002</offsets></xref><offsets xml_i="29525" xml_f="29527" txt_i="20745" txt_f="20747">).</offsets></p><p><offsets xml_i="29534" xml_f="29990" txt_i="20748" txt_f="21204">The extension of meaningful survival remains a major objective for oncologists who must therefore consider the impact of treatment-related toxicity. Overall, the occurrence of the toxicities in this study was consistent with the safety profiles of irinotecan, etoposide and 5-FU/LV. The ILF combination was well tolerated with a low and acceptable incidence of haematological toxicity. Gastrointestinal toxicity is a recognised side effect of ILF therapy (</offsets><xref ref-type="other" rid="bib8"><offsets xml_i="30024" xml_f="30034" txt_i="21204" txt_f="21214">Douillard </offsets><italic><offsets xml_i="30042" xml_f="30047" txt_i="21214" txt_f="21219">et al</offsets></italic><offsets xml_i="30056" xml_f="30062" txt_i="21219" txt_f="21225">, 2000</offsets></xref><offsets xml_i="30069" xml_f="30071" txt_i="21225" txt_f="21227">; </offsets><xref ref-type="other" rid="bib22"><offsets xml_i="30106" xml_f="30112" txt_i="21227" txt_f="21233">Saltz </offsets><italic><offsets xml_i="30120" xml_f="30125" txt_i="21233" txt_f="21238">et al</offsets></italic><offsets xml_i="30134" xml_f="30140" txt_i="21238" txt_f="21244">, 2000</offsets></xref><offsets xml_i="30147" xml_f="30217" txt_i="21244" txt_f="21314">), which can require hospitalisation and urgent medical intervention (</offsets><xref ref-type="other" rid="bib21"><offsets xml_i="30252" xml_f="30263" txt_i="21314" txt_f="21325">Rothenberg </offsets><italic><offsets xml_i="30271" xml_f="30276" txt_i="21325" txt_f="21330">et al</offsets></italic><offsets xml_i="30285" xml_f="30291" txt_i="21330" txt_f="21336">, 2001</offsets></xref><offsets xml_i="30298" xml_f="30417" txt_i="21336" txt_f="21455">). The incidence of grade 3 or 4 diarrhoea in the current study was comparable to the previous data in gastric cancer (</offsets><xref ref-type="other" rid="bib2"><offsets xml_i="30451" xml_f="30458" txt_i="21455" txt_f="21462">Blanke </offsets><italic><offsets xml_i="30466" xml_f="30471" txt_i="21462" txt_f="21467">et al</offsets></italic><offsets xml_i="30480" xml_f="30486" txt_i="21467" txt_f="21473">, 2001</offsets></xref><offsets xml_i="30493" xml_f="30495" txt_i="21473" txt_f="21475">; </offsets><xref ref-type="other" rid="bib15"><offsets xml_i="30530" xml_f="30538" txt_i="21475" txt_f="21483">Moehler </offsets><italic><offsets xml_i="30546" xml_f="30551" txt_i="21483" txt_f="21488">et al</offsets></italic><offsets xml_i="30560" xml_f="30566" txt_i="21488" txt_f="21494">, 2003</offsets></xref><offsets xml_i="30573" xml_f="30575" txt_i="21494" txt_f="21496">; </offsets><xref ref-type="other" rid="bib18"><offsets xml_i="30610" xml_f="30616" txt_i="21496" txt_f="21502">Pozzo </offsets><italic><offsets xml_i="30624" xml_f="30629" txt_i="21502" txt_f="21507">et al</offsets></italic><offsets xml_i="30638" xml_f="30644" txt_i="21507" txt_f="21513">, 2004</offsets></xref></p><p><offsets xml_i="30658" xml_f="30735" txt_i="21514" txt_f="21591">The toxicity observed in our study was lower than that reported by Douillard </offsets><italic><offsets xml_i="30743" xml_f="30748" txt_i="21591" txt_f="21596">et al</offsets></italic><offsets xml_i="30757" xml_f="30872" txt_i="21596" txt_f="21711"> in the pivotal European first-line trial where patients with colorectal cancer received weekly irinotecan (80 mg m</offsets><sup><offsets xml_i="30877" xml_f="30879" txt_i="21711" txt_f="21713">−2</offsets></sup><offsets xml_i="30885" xml_f="30946" txt_i="21713" txt_f="21774">) plus an AIO-based regimen of 24-h high-dose 5-FU (2300 mg m</offsets><sup><offsets xml_i="30951" xml_f="30953" txt_i="21774" txt_f="21776">−2</offsets></sup><offsets xml_i="30959" xml_f="30988" txt_i="21776" txt_f="21805">) preceded by 2-h LV 500 mg m</offsets><sup><offsets xml_i="30993" xml_f="30995" txt_i="21805" txt_f="21807">−2</offsets></sup><offsets xml_i="31001" xml_f="31060" txt_i="21807" txt_f="21866">, and grade 3/4 diarrhoea was reported by 44% of patients (</offsets><xref ref-type="other" rid="bib8"><offsets xml_i="31094" xml_f="31104" txt_i="21866" txt_f="21876">Douillard </offsets><italic><offsets xml_i="31112" xml_f="31117" txt_i="21876" txt_f="21881">et al</offsets></italic><offsets xml_i="31126" xml_f="31132" txt_i="21881" txt_f="21887">, 2000</offsets></xref><offsets xml_i="31139" xml_f="31230" txt_i="21887" txt_f="21978">). The lower toxicity in our study might be due to the lower daily doses of 5-FU (2000 mg m</offsets><sup><offsets xml_i="31235" xml_f="31237" txt_i="21978" txt_f="21980">−2</offsets></sup><offsets xml_i="31243" xml_f="31505" txt_i="21980" txt_f="22242"> administered over 24 h). Work is ongoing to identify those patients who carry a specific genetic polymorphism in one of the main enzymes (UGT1A1) involved in the detoxification of irinotecan and are therefore more susceptible to the side effects of irinotecan (</offsets><xref ref-type="other" rid="bib14"><offsets xml_i="31540" xml_f="31551" txt_i="22242" txt_f="22253">Mathijssen </offsets><italic><offsets xml_i="31559" xml_f="31564" txt_i="22253" txt_f="22258">et al</offsets></italic><offsets xml_i="31573" xml_f="31579" txt_i="22258" txt_f="22264">, 2001</offsets></xref><offsets xml_i="31586" xml_f="31728" txt_i="22264" txt_f="22406">). Such work will improve the targeting of this useful therapy and may allow appropriate prescriptive dosing schedules on an individual basis.</offsets></p><p><offsets xml_i="31735" xml_f="31977" txt_i="22407" txt_f="22649">The present study concurs with similar phase II studies in that the combination of irinotecan with continuous LV/5-FU (ILF) represents a potentially valuable new treatment option for metastatic gastric cancer and requires further evaluation (</offsets><xref ref-type="other" rid="bib4"><offsets xml_i="32011" xml_f="32018" txt_i="22649" txt_f="22656">Bouche </offsets><italic><offsets xml_i="32026" xml_f="32031" txt_i="22656" txt_f="22661">et al</offsets></italic><offsets xml_i="32040" xml_f="32046" txt_i="22661" txt_f="22667">, 2004</offsets></xref><offsets xml_i="32053" xml_f="32055" txt_i="22667" txt_f="22669">; </offsets><xref ref-type="other" rid="bib18"><offsets xml_i="32090" xml_f="32096" txt_i="22669" txt_f="22675">Pozzo </offsets><italic><offsets xml_i="32104" xml_f="32109" txt_i="22675" txt_f="22680">et al</offsets></italic><offsets xml_i="32118" xml_f="32124" txt_i="22680" txt_f="22686">, 2004</offsets></xref><offsets xml_i="32131" xml_f="32133" txt_i="22686" txt_f="22688">).</offsets></p></sec></body><back><ack><p>This work was supported by a grant from Aventis Pharma GmbH. The data from this study were presented previously at the American Society for Clinical Oncology annual meeting, 2004, Abstract No: 4064. We thank Dr A Kranich, GSO Hamburg, for supporting efficient monitoring, and Aventis Pharma Deutschland for supporting grants. We also thank all participating colleagues and centres: Markus Moehler<sup>1</sup>, Thomas Höhler<sup>1</sup>, Wolfgang Dippold<sup>2</sup>, Heinz-Albert Dürk<sup>3</sup>, Wolfgang Fischbach<sup>4</sup>, Thomas Geer<sup>5</sup>, Frank Gieseler<sup>6</sup>, Eckhart-Georg Hahn<sup>7</sup>, Michael Heike<sup>8</sup>, Hans-Jochen Illiger<sup>9</sup>, Joachim Mössner<sup>10</sup>, Rainer Porschen<sup>11</sup>, Jürgen Riemann<sup>12</sup>, Tilman Sauerbruch<sup>13</sup>, Wolff Schmiegel<sup>14</sup>, Wolfgang Stremmel<sup>15</sup>, Ziad Zeidan<sup>16</sup>, Stefan Zeuzem<sup>17</sup></p><p><sup>1</sup>Klinikum der Johannes-Gutenberg-Universität, I Medizinische Klinik und Poliklinik, Mainz, Germany; <sup>2</sup>Katholisches Klinikum Mainz, St Vincenz- und Elisabeth-Hospital, Mainz, Germany; <sup>3</sup>Sankt Marien Hospital, Medizinische Klinik, Hamm, Germany; <sup>4</sup>Klinikum Aschaffenburg, Medizinische Klinik, Germany; <sup>5</sup>Diakonie Krankenhaus, Schwäbisch Hall, Germany; <sup>6</sup>Universitätsklinikum Kiel, I Medizinische Klinik und Poliklinik, Germany; <sup>7</sup>Universitätsklinik Erlangen, NOZ Medizinische Klinik I, Erlangen, Germany; <sup>8</sup>Klinikum Dortmund gGmbH, Medizinische Klinik Mitte, Germany; <sup>9</sup>Klinikum Oldenburg gGmbH, Klinik für Innere Medizin, Germany; <sup>10</sup>Universität Leipzig, Medizinische Klinik und Poliklinik II, Germany; <sup>11</sup>Zentralkrankenhaus Bremen Ost, Germany; <sup>12</sup>Klinikum der Stadt Ludwigshafen, Germany; <sup>13</sup>Rheinische Friedrisch-Willhelms-Universität Bonn, I Medizinische Klinik, Germany; <sup>14</sup>Ruhr-Universität Bochum, Medizinische Universitätsklinik, Knappschaftskrankenhaus, Germany; <sup>15</sup>Universitätsklinikum Heidelberg, Medizinische Klinik IV, Germany; <sup>16</sup>Städtisches Klinikum Esslingen, Germany; <sup>17</sup>Universitätskliniken des Saarlandes, Innere Medizin II, Homburg, Germany.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assersohn</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>G</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Ward</surname><given-names>C</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Waters</surname><given-names>JS</given-names></name><name><surname>Hill</surname><given-names>ME</given-names></name><name><surname>Norman</surname><given-names>AR</given-names></name></person-group><article-title>Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma</article-title><source>Ann Oncol</source><year>2004</year><volume>15</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">14679122</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanke</surname><given-names>CD</given-names></name><name><surname>Haller</surname><given-names>DG</given-names></name><name><surname>Benson</surname><given-names>AB</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Berlin</surname><given-names>J</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>YC</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>1575</fpage><lpage>1580</lpage><pub-id pub-id-type="pmid">11822757</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blot</surname><given-names>WJ</given-names></name><name><surname>Devesa</surname><given-names>SS</given-names></name><name><surname>Kneller</surname><given-names>RW</given-names></name><name><surname>Fraumeni</surname><given-names>JFJ</given-names></name></person-group><article-title>Rising incidence of adenocarcinoma of the esophagus and gastric cardia</article-title><source>JAMA</source><year>1991</year><volume>265</volume><fpage>1287</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">1995976</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><name><surname>Giovannini</surname><given-names>M</given-names></name><name><surname>Etienne</surname><given-names>PL</given-names></name><name><surname>Lledo</surname><given-names>G</given-names></name><name><surname>Arsene</surname><given-names>D</given-names></name><name><surname>Paitel</surname><given-names>JF</given-names></name><name><surname>Guerin-Meyer</surname><given-names>V</given-names></name><name><surname>Mitry</surname><given-names>E</given-names></name><name><surname>Buecher</surname><given-names>B</given-names></name><name><surname>Kaminsky</surname><given-names>MC</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Bedenne</surname><given-names>L</given-names></name><name><surname>Milan</surname><given-names>C</given-names></name></person-group><article-title>Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>4319</fpage><lpage>4328</lpage><pub-id pub-id-type="pmid">15514373</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouzid</surname><given-names>K</given-names></name><name><surname>Khalfallah</surname><given-names>S</given-names></name><name><surname>Tujakowski</surname><given-names>J</given-names></name><name><surname>Piko</surname><given-names>B</given-names></name><name><surname>Purkalne</surname><given-names>G</given-names></name><name><surname>Padrik</surname><given-names>P</given-names></name><name><surname>Serafy</surname><given-names>M</given-names></name><name><surname>Pshevloutsky</surname><given-names>EM</given-names></name><name><surname>Boussard</surname><given-names>B</given-names></name></person-group><article-title>A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>1106</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">12853354</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Sankila</surname><given-names>R</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>Estimates of cancer incidence and mortality in Europe in 1995</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><fpage>99</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">11750846</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name></person-group><article-title>New chemotherapeutic advanced in pancreatic, colorectal, and gastric cancers</article-title><source>The Oncologist</source><year>2004</year><volume>9</volume><fpage>282</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">15169983</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Karasek</surname><given-names>P</given-names></name><name><surname>Jandik</surname><given-names>P</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Alakl</surname><given-names>M</given-names></name><name><surname>Gruia</surname><given-names>G</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name></person-group><article-title>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1041</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">10744089</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Futatsuki</surname><given-names>K</given-names></name><name><surname>Wakui</surname><given-names>A</given-names></name><name><surname>Nakao</surname><given-names>I</given-names></name><name><surname>Sakata</surname><given-names>Y</given-names></name><name><surname>Kambe</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Yoshino</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>N</given-names></name></person-group><article-title>Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group</article-title><source>Gan To Kagaku Ryoho</source><year>1994</year><volume>21</volume><fpage>1033</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">8210254</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Ekstrom</surname><given-names>K</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Sjoden</surname><given-names>PO</given-names></name><name><surname>Haglund</surname><given-names>U</given-names></name><name><surname>Svensson</surname><given-names>C</given-names></name><name><surname>Enander</surname><given-names>LK</given-names></name><name><surname>Linne</surname><given-names>T</given-names></name><name><surname>Sellstrom</surname><given-names>H</given-names></name><name><surname>Heuman</surname><given-names>R</given-names></name></person-group><article-title>Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer</article-title><source>Ann Oncol</source><year>1997</year><volume>8</volume><fpage>163</fpage><lpage>168</lpage></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hohenberger</surname><given-names>P</given-names></name><name><surname>Gretschel</surname><given-names>S</given-names></name></person-group><article-title>Gastric cancer</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">12892963</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohne</surname><given-names>CH</given-names></name><name><surname>Catane</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>B</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Thuss-Patience</surname><given-names>P</given-names></name><name><surname>Niederle</surname><given-names>N</given-names></name><name><surname>Gips</surname><given-names>M</given-names></name><name><surname>Preusser</surname><given-names>P</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>Clemens</surname><given-names>M</given-names></name><name><surname>Bugat</surname><given-names>R</given-names></name><name><surname>Figer</surname><given-names>I</given-names></name><name><surname>Shani</surname><given-names>A</given-names></name><name><surname>Fages</surname><given-names>B</given-names></name><name><surname>Di Betta</surname><given-names>D</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Wilke</surname><given-names>HJ</given-names></name></person-group><article-title>Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">12966415</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name></person-group><article-title>Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15188010</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathijssen</surname><given-names>RH</given-names></name><name><surname>van Alphen</surname><given-names>RJ</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Loos</surname><given-names>WJ</given-names></name><name><surname>Nooter</surname><given-names>K</given-names></name><name><surname>Stoter</surname><given-names>G</given-names></name><name><surname>Sparreboom</surname><given-names>A</given-names></name></person-group><article-title>Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>2182</fpage><lpage>2194</lpage><pub-id pub-id-type="pmid">11489791</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>U</given-names></name><name><surname>Siebler</surname><given-names>J</given-names></name><name><surname>Schimanski</surname><given-names>C</given-names></name><name><surname>Hertkorn</surname><given-names>C</given-names></name><name><surname>Hoehler</surname><given-names>T</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Heike</surname><given-names>M</given-names></name></person-group><article-title>Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer</article-title><source>Anticancer Drugs</source><year>2003</year><volume>14</volume><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">14501387</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>AM</given-names></name><name><surname>Santiago</surname><given-names>FF</given-names></name><name><surname>Petroianu</surname><given-names>A</given-names></name><name><surname>Rocha</surname><given-names>PR</given-names></name><name><surname>Rodrigues</surname><given-names>MA</given-names></name><name><surname>Rausch</surname><given-names>M</given-names></name></person-group><article-title>Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer</article-title><source>Cancer</source><year>1993</year><volume>72</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">8508427</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name></person-group><article-title>A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><fpage>1329</fpage><lpage>1333</lpage><pub-id pub-id-type="pmid">15054450</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pozzo</surname><given-names>C</given-names></name><name><surname>Barone</surname><given-names>C</given-names></name><name><surname>Szanto</surname><given-names>J</given-names></name><name><surname>Padi</surname><given-names>E</given-names></name><name><surname>Peschel</surname><given-names>C</given-names></name><name><surname>Bukki</surname><given-names>J</given-names></name><name><surname>Gorbunova</surname><given-names>V</given-names></name><name><surname>Valvere</surname><given-names>V</given-names></name><name><surname>Zaluski</surname><given-names>J</given-names></name><name><surname>Biakhov</surname><given-names>M</given-names></name><name><surname>Zuber</surname><given-names>E</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Bugat</surname><given-names>R</given-names></name></person-group><article-title>Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study</article-title><source>Ann Oncol</source><year>2004</year><volume>15</volume><fpage>1773</fpage><lpage>1781</lpage><pub-id pub-id-type="pmid">15550582</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>Kuitunen</surname><given-names>T</given-names></name><name><surname>Nyandoto</surname><given-names>P</given-names></name><name><surname>Kouri</surname><given-names>M</given-names></name></person-group><article-title>Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>587</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">7533517</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rau</surname><given-names>B</given-names></name><name><surname>Hunerbein</surname><given-names>M</given-names></name><name><surname>Reingruber</surname><given-names>B</given-names></name><name><surname>Hohenberger</surname><given-names>P</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name></person-group><article-title>Laparoscopic lymph node assessment in pretherapeutic staging of gastric and esophageal cancer</article-title><source>Rec Res Cancer Res</source><year>1996</year><volume>142</volume><fpage>209</fpage><lpage>215</lpage></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Meropol</surname><given-names>NJ</given-names></name><name><surname>Poplin</surname><given-names>E</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Walder</surname><given-names>S</given-names></name></person-group><article-title>Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>3801</fpage><lpage>3807</lpage><pub-id pub-id-type="pmid">11559717</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">11006366</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoffski</surname><given-names>P</given-names></name></person-group><article-title>New drugs for treatment of gastric cancer</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><supplement>suppl 4</supplement><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12401661</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulze-Bergkamen</surname><given-names>H</given-names></name><name><surname>Zuna</surname><given-names>I</given-names></name><name><surname>Tuefel</surname><given-names>A</given-names></name><name><surname>Stremmel</surname><given-names>W</given-names></name><name><surname>Rudi</surname><given-names>J</given-names></name></person-group><article-title>Treatment of advanced gastric cancer with etoposide, folinic acid and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumour markers</article-title><source>Med Oncol</source><year>2002</year><volume>19</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">12025890</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">10655437</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Ducreux</surname><given-names>MP</given-names></name><name><surname>Lacave</surname><given-names>AJ</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Planker</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>JG</given-names></name><name><surname>Piedbois</surname><given-names>P</given-names></name><name><surname>Paillot</surname><given-names>B</given-names></name><name><surname>Bodenstein</surname><given-names>H</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Couvreur</surname><given-names>ML</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Wils</surname><given-names>JA</given-names></name></person-group><article-title>Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin <italic>versus</italic> etoposide, leucovorin, and fluorouracil <italic>versus</italic> infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2648</fpage><lpage>2657</lpage><pub-id pub-id-type="pmid">10894863</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>JS</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Scarffe</surname><given-names>JH</given-names></name><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Harper</surname><given-names>P</given-names></name><name><surname>Joffe</surname><given-names>JK</given-names></name><name><surname>Mackean</surname><given-names>M</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Leahy</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name></person-group><article-title>Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial</article-title><source>Br J Cancer</source><year>1999</year><volume>80</volume><fpage>269</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">10390007</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Overall survival. Arm A=irinotecan+5-fluorouracil/leucovorin (ILF), <italic>N</italic>=56. Arm B=etoposide+5-fluorouracil/leucovorin (ELF), <italic>N</italic>=58.</p></caption><graphic mime-subtype="gif" xlink:href="92-6602649f1"></graphic></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient and disease characteristics at baseline (intention-to-treat population)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50"><bold>Irinotecan+5-FU/LV</bold></th><th align="center" valign="top" charoff="50"><bold>Etoposide+5-FU/LV</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">No. of exposed patients</td><td align="center" valign="top" charoff="50">56</td><td align="center" valign="top" charoff="50">58</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Gender (n (%))</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Male</td><td align="center" valign="top" charoff="50">40 (71)</td><td align="center" valign="top" charoff="50">49 (85)</td></tr><tr><td align="left" valign="top" charoff="50"> Female</td><td align="center" valign="top" charoff="50">16 (29)</td><td align="center" valign="top" charoff="50">9 (16)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Age (years)</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Median (range)</td><td align="center" valign="top" charoff="50">61 (41–73)</td><td align="center" valign="top" charoff="50">63 (34–76)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>KPS</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Median value</td><td align="center" valign="top" charoff="50">90</td><td align="center" valign="top" charoff="50">85</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Distribution (n (%))</italic></td></tr><tr><td align="left" valign="top" charoff="50"> 60+70</td><td align="center" valign="top" charoff="50">3 (5)</td><td align="center" valign="top" charoff="50">7 (12)</td></tr><tr><td align="left" valign="top" charoff="50"> 80</td><td align="center" valign="top" charoff="50">21 (38)</td><td align="center" valign="top" charoff="50">22 (38)</td></tr><tr><td align="left" valign="top" charoff="50"> 90</td><td align="center" valign="top" charoff="50">28 (50)</td><td align="center" valign="top" charoff="50">21 (36)</td></tr><tr><td align="left" valign="top" charoff="50"> 100</td><td align="center" valign="top" charoff="50">4 (7)</td><td align="center" valign="top" charoff="50">8 (14)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Primary tumour location (n (%))</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Stomach</td><td align="center" valign="top" charoff="50">37 (66)</td><td align="center" valign="top" charoff="50">42 (72)</td></tr><tr><td align="left" valign="top" charoff="50"> Oesophagogastric junction</td><td align="center" valign="top" charoff="50">19 (34)</td><td align="center" valign="top" charoff="50">16 (28)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Median time (months (range)) since</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Histological confirmation</td><td align="center" valign="top" charoff="50">1.5 (0–181)</td><td align="center" valign="top" charoff="50">1.4 (0–65)</td></tr><tr><td align="left" valign="top" charoff="50"> Diagnosis of metastasis</td><td align="center" valign="top" charoff="50">0.7 (0–12)</td><td align="center" valign="top" charoff="50">0.5 (0–13)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Prior surgery</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Number with surgery (%)</td><td align="center" valign="top" charoff="50">29 (52)</td><td align="center" valign="top" charoff="50">31 (53)</td></tr><tr><td align="left" valign="top" charoff="50"> Median months since surgery (range)</td><td align="center" valign="top" charoff="50">7.7 (0–181)</td><td align="center" valign="top" charoff="50">11.1 (0–65)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Location of metastases at entry (n (%))</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Skin</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1 (2)</td></tr><tr><td align="left" valign="top" charoff="50"> Liver</td><td align="center" valign="top" charoff="50">34 (61)</td><td align="center" valign="top" charoff="50">37 (64)</td></tr><tr><td align="left" valign="top" charoff="50"> Lung</td><td align="center" valign="top" charoff="50">12 (21)</td><td align="center" valign="top" charoff="50">5 (9)</td></tr><tr><td align="left" valign="top" charoff="50"> Lymph nodes</td><td align="center" valign="top" charoff="50">40 (71)</td><td align="center" valign="top" charoff="50">47 (81)</td></tr><tr><td align="left" valign="top" charoff="50"> Bone marrow</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Bone</td><td align="center" valign="top" charoff="50">4 (7)</td><td align="center" valign="top" charoff="50">1 (2)</td></tr><tr><td align="left" valign="top" charoff="50"> Peritoneum</td><td align="center" valign="top" charoff="50">10 (18)</td><td align="center" valign="top" charoff="50">11 (19)</td></tr><tr><td align="left" valign="top" charoff="50"> Other</td><td align="center" valign="top" charoff="50">20 (36)</td><td align="center" valign="top" charoff="50">23 (40)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Number of involved organs (n (%))</italic></td></tr><tr><td align="left" valign="top" charoff="50"> 1</td><td align="center" valign="top" charoff="50">13 (23)</td><td align="center" valign="top" charoff="50">13 (22)</td></tr><tr><td align="left" valign="top" charoff="50"> 2</td><td align="center" valign="top" charoff="50">25 (45)</td><td align="center" valign="top" charoff="50">25 (43)</td></tr><tr><td align="left" valign="top" charoff="50"> 3</td><td align="center" valign="top" charoff="50">15 (27)</td><td align="center" valign="top" charoff="50">18 (31)</td></tr><tr><td align="left" valign="top" charoff="50"> 4</td><td align="center" valign="top" charoff="50">3 (5)</td><td align="center" valign="top" charoff="50">2 (3)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label></label><p>KPS=Karnofsky performance score.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Response to therapy in the entire treatment period</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" charoff="50"><bold>Number (%) of patients</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Response category</bold></th><th align="center" valign="top" charoff="50"><bold>Irinotecan+5-FU/LV(<italic>N</italic>=56)</bold></th><th align="center" valign="top" charoff="50"><bold>Etoposide+5-FU/LV(<italic>N</italic>=58)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">CR</td><td align="center" valign="top" charoff="50">2 (4)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">22 (39)</td><td align="center" valign="top" charoff="50">14 (24)</td></tr><tr><td align="left" valign="top" charoff="50">NC</td><td align="center" valign="top" charoff="50">11 (20)</td><td align="center" valign="top" charoff="50">10 (17)</td></tr><tr><td align="left" valign="top" charoff="50">PD</td><td align="center" valign="top" charoff="50">13 (23)</td><td align="center" valign="top" charoff="50">27 (47)</td></tr><tr><td align="left" valign="top" charoff="50">Missing</td><td align="center" valign="top" charoff="50">8 (14)</td><td align="center" valign="top" charoff="50">7 (12)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Overall response (CR+PR)</td><td align="center" valign="top" charoff="50">24 (43)</td><td align="center" valign="top" charoff="50">14 (24)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">RR (95% CI), <italic>P</italic>-value</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50">0.56 (0.33–0.97), <italic>P</italic>=0.0467<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Disease control (CR+PR+NC)</td><td align="center" valign="top" charoff="50">35 (63)</td><td align="center" valign="top" charoff="50">24 (41)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote2"><label></label><p>5-FU=5-fluorouracil; LV=leucovorin; CR=Complete response; PR=partial response; NC=no change; PD=progressive disease; RR=risk ratio; CI=confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Exploratory analysis of effects of prognostic factors on clinical outcome</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="left"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>End point</bold></th><th align="left" valign="top" charoff="50"><bold>Factor</bold></th><th align="center" valign="top" charoff="50"><bold>RR (95% CI)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Response</td><td align="left" valign="top" charoff="50">Peritoneal involvement:</td><td align="center" valign="top" charoff="50">0.43</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Yes <italic>vs</italic> no</td><td align="center" valign="top" charoff="50">(0.13–1.47)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Surgery of primary tumour:</td><td align="center" valign="top" charoff="50">1.78</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Yes <italic>vs</italic> no</td><td align="center" valign="top" charoff="50">(0.76–4.15)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Baseline Karnofsky status:</td><td align="center" valign="top" charoff="50">0.41<sup>*</sup></td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">⩽80 <italic>vs</italic> &gt;80</td><td align="center" valign="top" charoff="50">(0.17–0.95)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Treatment effect:</td><td align="center" valign="top" charoff="50">0.42<sup>*</sup></td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">ELF <italic>vs</italic> ILF</td><td align="center" valign="top" charoff="50">(0.18–0.97)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Progression</td><td align="left" valign="top" charoff="50">Peritoneal involvement:</td><td align="center" valign="top" charoff="50">1.15</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Yes <italic>vs</italic> no</td><td align="center" valign="top" charoff="50">(0.67–1.96)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Surgery of primary tumour:</td><td align="center" valign="top" charoff="50">0.86</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Yes <italic>vs</italic> no</td><td align="center" valign="top" charoff="50">(0.58–1.29)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">ELF <italic>vs</italic> ILF</td><td align="center" valign="top" charoff="50">1.7</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">(in patients with Karnofsky status ⩽80)</td><td align="center" valign="top" charoff="50">(0.96–3.0)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">ELF <italic>vs</italic> ILF</td><td align="center" valign="top" charoff="50">0.8</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">(in patients with Karnofsky status &gt;80)</td><td align="center" valign="top" charoff="50">(0.47–1.39)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Number of organs:</td><td align="center" valign="top" charoff="50">1.99<sup>**</sup></td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">&gt;1 <italic>vs</italic> 1</td><td align="center" valign="top" charoff="50">(1.21–3.28)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Site of primary tumour:</td><td align="center" valign="top" charoff="50">1.91<sup>**</sup></td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">oesophagogastric <italic>vs</italic> stomach</td><td align="center" valign="top" charoff="50">(1.2–3.04)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Death</td><td align="left" valign="top" charoff="50">Peritoneal involvement:</td><td align="center" valign="top" charoff="50">0.85</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Yes <italic>vs</italic> no</td><td align="center" valign="top" charoff="50">(0.42–1.75)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Surgery of primary tumour:</td><td align="center" valign="top" charoff="50">0.69</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Yes <italic>vs</italic> no</td><td align="center" valign="top" charoff="50">(0.46–1.06)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">ELF <italic>vs</italic> ILF</td><td align="center" valign="top" charoff="50">2.41</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">(in patients with peritoneal involvement)</td><td align="center" valign="top" charoff="50">(0.99–5.82)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">ELF <italic>vs</italic> ILF</td><td align="center" valign="top" charoff="50">1.01</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">(in patients without peritoneal involvement)</td><td align="center" valign="top" charoff="50">(0.64–1.59)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Number of organs:</td><td align="center" valign="top" charoff="50">2.56<sup>**</sup></td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">&gt;1 <italic>vs</italic> 1</td><td align="center" valign="top" charoff="50">(1.48–4.42)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Baseline Karnofsky status:</td><td align="center" valign="top" charoff="50">1.84<sup>**</sup></td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">⩽80 <italic>vs</italic> &gt;80</td><td align="center" valign="top" charoff="50">(1.21–2.8)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote3"><label></label><p>RR=risk ratio; CI=confidence interval.</p></fn><fn id="tbfnote4"><label></label><p>A risk value &gt;1 shows an increased likelihood of the clinical outcome in favour of the first of the two compared terms. ELF, etoposide+LV (leucovorin)+5-FU(5-fluorouracil); ILF, irinotecan+LV+5-FU; EJ, oesophagogastric junction.</p></fn><fn id="tbfnote5"><label></label><p><sup>*</sup><italic>P</italic>&lt;0.05.</p></fn><fn id="tbfnote6"><label></label><p><sup>**</sup>&lt;0.01 by Wald <italic>χ</italic><sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Survival</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="left" valign="top" charoff="50"><bold>Irinotecan+5-FU/LV (<italic>N</italic>=56)</bold><hr></hr></th><th align="left" valign="top" charoff="50"><bold>Etoposide+5-FU/LV (<italic>N</italic>=58)</bold><hr></hr></th><th align="left" valign="top" charoff="50"> </th></tr><tr><th align="left" valign="top" charoff="50"><bold>Survivalparameter</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Median time in months (95% CI)</bold></th><th align="left" valign="top" charoff="50"><bold>Statisticalcomparison<sup>a</sup>Hazard ratio(95% CI)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Progression-free survival</td><td align="left" valign="top" charoff="50">4.5 (3.4–5.8)</td><td align="left" valign="top" charoff="50">2.3 (2.0–4.7)</td><td align="left" valign="top" charoff="50">1.10 (0.75–1.62)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"><italic>P</italic>=0.6116</td></tr><tr><td align="left" valign="top" charoff="50">Time to treatment failure</td><td align="left" valign="top" charoff="50">3.6 (2.4–5.1)</td><td align="left" valign="top" charoff="50">2.2 (1.5–2.9)</td><td align="left" valign="top" charoff="50">1.15 (0.79–1.67)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"><italic>P</italic>=0.4542</td></tr><tr><td align="left" valign="top" charoff="50">Overall survival</td><td align="left" valign="top" charoff="50">10.8 (9.0–13.2)</td><td align="left" valign="top" charoff="50">8.3 (6.6–11.4)</td><td align="left" valign="top" charoff="50">1.25 (0.83–1.86)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"><italic>P</italic>=0.2818</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote7"><label></label><p>5-FU=5-fluorouracil; LV=leucovorin; CI=confidence interval.</p></fn><fn id="tbfnote8"><label>a</label><p>Hazard ratio &gt;1 favors irinotecan+5-FU/LV; <italic>P</italic>-value from log-rank test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p content-type="table-title">Dosing information</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50"><bold>Irinotecan+5-FU/LV (<italic>N</italic>=56)</bold></th><th align="center" valign="top" charoff="50"><bold>Etoposide+5-FU/LV (<italic>N</italic>=58)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Median number of cycles (range)</td><td align="center" valign="top" charoff="50">2 (0–14)</td><td align="center" valign="top" charoff="50">3 (1–19)</td></tr><tr><td align="left" valign="top" charoff="50">Number of cycles administered as planned</td><td align="center" valign="top" charoff="50">33 (59%)</td><td align="center" valign="top" charoff="50">48 (82%)</td></tr><tr><td align="left" valign="top" charoff="50">Median months of treatment duration (range)</td><td align="center" valign="top" charoff="50">3.6 (0–22)</td><td align="center" valign="top" charoff="50">1.5 (0–15)</td></tr><tr><td align="left" valign="top" charoff="50">Number (%) of administration delays</td><td align="center" valign="top" charoff="50">39 (70)</td><td align="center" valign="top" charoff="50">30 (52)</td></tr><tr><td align="left" valign="top" charoff="50">Number (%) of dose reductions</td><td align="center" valign="top" charoff="50">42 (75)</td><td align="center" valign="top" charoff="50">26 (45)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote9"><label></label><p>5-FU=5-fluorouracil; LV=leucovorin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl6" position="float"><label>Table 6</label><caption><p content-type="table-title">Grade 3 or 4 toxicity according to NCIC-CTC</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="." charoff="50"><bold>Irinotecan+5-FU/LV (<italic>N</italic>=56)</bold><hr></hr></th><th align="char" valign="top" char="." charoff="50"><bold>Etoposide+5-FU/LV (<italic>N</italic>=58)</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Adverse event category</bold></th><th colspan="2" align="center" valign="top" char="." charoff="50"><bold>Percentage of patients in eachcategory</bold></th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Haematological toxicity</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Anaemia</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50"> Neutropenia</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">57</td></tr><tr><td align="left" valign="top" charoff="50"> Thrombocytopenia</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">5</td></tr><tr><td align="left" valign="top" charoff="50"> Infection with neutropenia</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50"> Fever+neutropenia, no infection</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Gastrointestinal toxicity</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Nausea</td><td align="char" valign="top" char="." charoff="50">16</td><td align="char" valign="top" char="." charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50"> Diarrhoea</td><td align="char" valign="top" char="." charoff="50">18</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Vomiting</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">5</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Other toxicity</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Infection without neutropenia</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50"> Anorexia</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50"> Alopecia</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">28</td></tr><tr><td align="left" valign="top" charoff="50"> Constipation</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote10"><label></label><p>NCIC-CTC=National Cancer Institute of Canada expanded common toxicity criteria; 5-FU=5-fluorouracil; LV=leucovorin.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>